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editorial
Is carboplatin–paclitaxel combination
the standard treatment of elderly
ovarian cancer patients?
Ovarian cancer is the leading cause of death from gynaecological
cancer in the Western world [1]. The majority of ovarian cancer
patients present with an advanced disease and show a 5-year
survival rate of 25%–30%. Cytoreductive surgery combined
with chemotherapy is the standard treatment of ovarian cancer.
Since the 1980s clinical trials demonstrated that platinum-based
chemotherapy improves survival in women with advanced
disease. Carboplatin and paclitaxel association is, by now, the
standard first-line chemotherapy regimen [2].
Improvement in health care and nutrition, decrease in global
mortality and increasing trends of mean-life expectancy result in
humans getting older compared with some decades ago. The
incidence of ovarian cancer rises with advancing age, peaking in
the seventh decade of life. Today, about half of all ovarian
cancers occur in women over the age of 65 [1].
Elderly patients are less likely to receive optimal treatment.
Moreover, comparing patients 70–79 years old with patients 80
years of age or older, Uyar et al. [3] reported that the extreme
elderly had a decreased likelihood of receiving surgery and
combination chemotherapy despite equivalent comorbidities.
Performing a meta-analysis, Bristow et al. [4] concluded that,
during the platinum era, maximal cytoreductive surgery is one
of the most powerful determinants of cohort survival among
patients with advanced ovarian carcinoma. Although age is an
independent prognostic factor, reduced surgical radicality
contributes to poorer outcome in advanced ovarian cancer
patients who are >65 years old [5]. A reason for suboptimal
surgical treatment in elderly patients could be a fear of higher
complication rates. In patients older than 80 years undergoing
debulking surgery, Cloven et al. [6] showed high morbidity and
prolonged hospitalisation, but most of the patients were
discharged their home and were able to receive postoperative
chemotherapy.
A recently published meta-analysis of chemotherapy regimens
for ovarian cancer reported a doubling or more of time to
mortality with platinum and taxane combinations [7].
Evaluating the effects of age and comorbidity on the application
of treatment guidelines, Maas et al. [8] reported that even in the
absence of comorbidity standard combination chemotherapy
was prescribed significantly less often for elderly patients (‡70
years). Since 1983 the Eastern Cooperative Oncology Group
concluded that the apparent discrimination in not treating
elderly cancer patients as aggressively as younger patients did
not appear to be justified [9]. In a retrospective toxicity
multicentre study, chronological age did not adversely influence
the ability to receive aggressive chemotherapy treatment in
gynaecological malignancies [10]. Higgins et al. [11], comparing
toxic effects of carboplatin and paclitaxel combination in
patients less or >60 years old (60–78), concluded that age is not
a barrier to the aggressive treatment of ovarian cancer with this
regimen. In the study of Vilella et al. [12] women older than 70
years tolerated therapeutic doses of carboplatin and paclitaxel
combination. Furthermore, platinum–paclitaxel combination is
effective in elderly patients [13].
In the article published in the current issue, Tredan et al. [14]
report that they do not consider carboplatin–paclitaxel (CP)
combination as standard chemotherapy for elderly ovarian
cancer patients. They compared two consecutive series of
patient’s ‡70 years old to evaluate the feasibility of two different
polychemotherapy schedules. Eighty-three patients, in 30
centres, were treated with carboplatin plus cyclophosphamide
(CC) administered every 4 weeks and 75 further patients, in 23
centres, received CP every 3 weeks. Comprehensive Geriatric
Assessment (CGA) was carried out at study entry. More patients
in the CC group presented with performance status of more than
two, depression symptoms, use of comedications,
hypoalbuminemia, abnormal Mini-Mental Status (MMS) score
or suboptimal surgery. Both regimens appeared feasible (75.6%
in the CC group and 68.1% in the CP group completed six
courses) and the overall survival (OS) was similar in the two
groups. Independent prognostic factors of poorer OS were:
increasing age (P = 0.013), depression symptoms at baseline
(P < 0.001), International Federation of Gynaecology and
Obstetrics stage IV (P = 0.001) and use of paclitaxel (P = 0.025).
Women in the CC group were less likely to experience
neutropenia compared with the women treated by the CP
combination (8.1% versus 52.8%, P < 0.001), but more likely to
have reduced platelets (39.5% of patients with <50 · 109/l in this
group versus 9.7% in the CP group, P < 0.001). Low rates of
grade 3–4 non-haematological toxicity were observed for both
regimens, except alopecia, neurosensory and neuromotor
toxicity were worse with the CP regimen. The authors concluded
that the use of paclitaxel in a group of better prognosis resulted
in more toxicity without evidence of improvement in OS.
The major bias of this study is the nonrandomised design,
that could compromise the final results. The different schedule
(4 weeks for CC and 3 weeks for CP) could underestimate the
toxicity in the CC group, although the authors underline that it
is comparable with most of the prospective studies evaluating
the CP combination in advanced ovarian cancer. Also these data
could be more precisely evaluated within a randomised trial.
Furthermore, carboplatin–cyclophosphamide combination is
not the standard treatment of ovarian cancer, also in elderly
patients [15].
e
d
it
o
ri
a
l
ª 2007 European Society for Medical Oncology
 at U
ni Torino D
ip Sanità Pubblica M
icrobiologia on O
ctober 31, 2012
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Elderly patients are less likely to be entered into clinical trials
[16]. Compared with their younger counterparts, patient’s ‡65
years of age with stage III/IV disease were less likely to enter into
a Gynecologic Oncology Group (GOG) treatment protocol.
Most common reasons were patient’s ineligibility (33%), refusal
(29%) and investigator decision (20%). The GOG proposed, in
addition to reviewing eligibility criteria, that practitioners’
attitudes should be monitored to assure elderly patients were not
being inappropriately denied participation in clinical trials [17].
An interesting aspect of this trial is the evaluation of the
prognostic role of CGA parameters. The authors showed
previously that CGA could predict severe toxicity and OS of
advanced ovarian cancer patients over the age of 70 years using
the carboplatin and CC combination [18]. In the present study,
CGA included evaluation of patient dependence, comedication
defined as the number of different drugs taken daily (0–3, 4–6 or
>6), nutritional status (total protein, albumin, prealbumin,
C-reactive protein and orosomucoid) and cognitive function
using the MMS; presence or absence of clinical symptoms of
depression were also evaluated. The authors conclude that CGA
parameters and particularly emotional disorders might help to
determine a priori the risk/benefit ratio of chemotherapy. Chen
et al. in a prospective pilot study reported that older cancer
patients (‡70 years) undergoing chemotherapy may experience
toxicity but generally are able to tolerate it with limited impact
on independence, comorbidity and quality-of-life levels. They
concluded that a CGA is very useful in detecting treatment-
related changes in geriatric oncology patients and should be
incorporated into clinical outcome analysis [19]. Prospective
trials on elderly patients should take into account CGA
parameters in order to predict efficacy and tolerance of
treatment.
In conclusion, there is no evidence for not treating elderly
ovarian cancer patients with the standard treatment or
excluding them from randomised clinical trials. Carboplatin–
paclitaxel combination is, by now, the standard treatment of
ovarian cancer. Trials should be designed to define the better
treatment of this subset of patients.
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